Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000515628 http://scihub22266oqcxt.onion/10.1159/000515628 33857940!8089445!33857940     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Blood+Purif 2022 ; 51 (1): 47-54 Nephropedia Template TP {{tp|p=33857940|t=2022. Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia |pdf=|usr=}}{{33857940}} gab.com Text Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia JO: Blood Purif http://www.kidney.de/pget.php?&tw=1&pmid=33857940 #FOAvip INTRODUCTION: Uncontrolled systemic inflammation may occur in severe coronavirus disease 19 (COVID-19). We have previously shown that endotoxemia, presumably from the gut, may complicate COVID-19. However, the role of endotoxin adsorbent (EA) therapy to mitigate organ dysfunction in COVID-19 has not been explored. METHODS: We conducted a retrospective observational study in COVID-19 patients who received EA therapy at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between March 13 and April 17, 2020. Relevant clinical and laboratory data were collected by inpatient chart review. RESULTS: Among 147 hospitalized COVID-19 patients, 6 patients received EA therapy. All of the 6 patients had severe COVID-19 infection with acute respiratory distress syndrome (ARDS). Among these, 5 of them were mechanically ventilated and 4 had complications of secondary bacterial infection. The endotoxin activity assay (EAA) results of pre-EA therapy ranged from 0.47 to 2.79. The choices of EA therapy were at the discretion of attending physicians. One patient was treated with oXiris(R) along with continuous renal replacement therapy, and the others received polymyxin B hemoperfusion sessions. All patients have survived and were finally free from the mechanical ventilation as well as had improvement in PaO2/FiO2 ratio and decreased EAA level after EA therapy. CONCLUSIONS: We demonstrated the clinical improvement of severe COVID-19 patients with elevated EAA level upon receiving EA therapy. However, the benefit of EA therapy in COVID-19 ARDS is still unclear and needs to be elucidated with randomized controlled study. Twit Text FOAVip Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia ????Blood Purif http://www.kidney.de/pget.php?&tw=1&pmid=33857940 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33857940 #FOAvip English Wikipedia <ref>{{Cite pmid|33857940}}</ref> Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia #MMPMID33857940 Peerapornratana S; Sirivongrangson P; Tungsanga S; Tiankanon K; Kulvichit W; Putcharoen O; Kellum JA; Srisawat N Blood Purif 2022[]; 51 (1): 47-54 PMID33857940show ga INTRODUCTION: Uncontrolled systemic inflammation may occur in severe coronavirus disease 19 (COVID-19). We have previously shown that endotoxemia, presumably from the gut, may complicate COVID-19. However, the role of endotoxin adsorbent (EA) therapy to mitigate organ dysfunction in COVID-19 has not been explored. METHODS: We conducted a retrospective observational study in COVID-19 patients who received EA therapy at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between March 13 and April 17, 2020. Relevant clinical and laboratory data were collected by inpatient chart review. RESULTS: Among 147 hospitalized COVID-19 patients, 6 patients received EA therapy. All of the 6 patients had severe COVID-19 infection with acute respiratory distress syndrome (ARDS). Among these, 5 of them were mechanically ventilated and 4 had complications of secondary bacterial infection. The endotoxin activity assay (EAA) results of pre-EA therapy ranged from 0.47 to 2.79. The choices of EA therapy were at the discretion of attending physicians. One patient was treated with oXiris(R) along with continuous renal replacement therapy, and the others received polymyxin B hemoperfusion sessions. All patients have survived and were finally free from the mechanical ventilation as well as had improvement in PaO2/FiO2 ratio and decreased EAA level after EA therapy. CONCLUSIONS: We demonstrated the clinical improvement of severe COVID-19 patients with elevated EAA level upon receiving EA therapy. However, the benefit of EA therapy in COVID-19 ARDS is still unclear and needs to be elucidated with randomized controlled study. |*SARS-CoV-2[MESH] |Acute Kidney Injury/etiology/therapy[MESH] |Adsorption[MESH] |COVID-19/complications/*therapy[MESH] |Critical Care/methods[MESH] |Endotoxemia/etiology/*therapy[MESH] |Female[MESH] |Hemoperfusion/*methods[MESH] |Heparin/administration & dosage[MESH] |Humans[MESH] |Male[MESH] |Membranes, Artificial[MESH] |Middle Aged[MESH] |Polymyxin B/administration & dosage[MESH] |Renal Replacement Therapy[MESH] |Respiratory Distress Syndrome/etiology[MESH] |Retrospective Studies[MESH]Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia (epmc).pdf DeepDyve Pubget Overpricing